Abstract
Cell-proliferation markers are very important in the clinical management of cancer patients, and the identification of Ki-67 (a monoclonal antibody that recognizes proliferating cells) can make it easier to define the level of proliferative activity. This study investigated the associations between the Ki-67 levels measured by means of immunohistochemistry, and other clinical and pathological variables and prognosis in 322 breast-cancer patients. A significant association was found (p <0.001) between Ki-67 values and tumor size, nodal status, estrogen and progesterone receptor status; multivariate analysis showed that Ki-67 levels were associated with disease-free and overall survival, thus confirming that it is an independent prognostic variable. Various statistical approaches were used in an attempt to establish the best cut-off point for dividing patients into groups at high or low risk of relapse but, in this series, we could find no evidence leading to a single 'best' cut-off point. We conclude that the quantitative level of Ki-67 could be used as a prognostic factor in breast-cancer patients.
| Original language | English |
|---|---|
| Pages (from-to) | 433-437 |
| Number of pages | 5 |
| Journal | International Journal of Cancer |
| Volume | 74 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 1997 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Ki-67 immunostaining in 322 primary breast cancers : Associations with clinical and pathological variables and prognosis. / Molino, Annamaria; Micciolo, Rocco; Turazza, Monica; Bonetti, Franco; Piubello, Quirino; Bonetti, Andrea; Nortilli, Rolando; Pelosi, Giuseppe; Cetto, Gian Luigi.
In: International Journal of Cancer, Vol. 74, No. 4, 1997, p. 433-437.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Ki-67 immunostaining in 322 primary breast cancers
T2 - Associations with clinical and pathological variables and prognosis
AU - Molino, Annamaria
AU - Micciolo, Rocco
AU - Turazza, Monica
AU - Bonetti, Franco
AU - Piubello, Quirino
AU - Bonetti, Andrea
AU - Nortilli, Rolando
AU - Pelosi, Giuseppe
AU - Cetto, Gian Luigi
PY - 1997
Y1 - 1997
N2 - Cell-proliferation markers are very important in the clinical management of cancer patients, and the identification of Ki-67 (a monoclonal antibody that recognizes proliferating cells) can make it easier to define the level of proliferative activity. This study investigated the associations between the Ki-67 levels measured by means of immunohistochemistry, and other clinical and pathological variables and prognosis in 322 breast-cancer patients. A significant association was found (p <0.001) between Ki-67 values and tumor size, nodal status, estrogen and progesterone receptor status; multivariate analysis showed that Ki-67 levels were associated with disease-free and overall survival, thus confirming that it is an independent prognostic variable. Various statistical approaches were used in an attempt to establish the best cut-off point for dividing patients into groups at high or low risk of relapse but, in this series, we could find no evidence leading to a single 'best' cut-off point. We conclude that the quantitative level of Ki-67 could be used as a prognostic factor in breast-cancer patients.
AB - Cell-proliferation markers are very important in the clinical management of cancer patients, and the identification of Ki-67 (a monoclonal antibody that recognizes proliferating cells) can make it easier to define the level of proliferative activity. This study investigated the associations between the Ki-67 levels measured by means of immunohistochemistry, and other clinical and pathological variables and prognosis in 322 breast-cancer patients. A significant association was found (p <0.001) between Ki-67 values and tumor size, nodal status, estrogen and progesterone receptor status; multivariate analysis showed that Ki-67 levels were associated with disease-free and overall survival, thus confirming that it is an independent prognostic variable. Various statistical approaches were used in an attempt to establish the best cut-off point for dividing patients into groups at high or low risk of relapse but, in this series, we could find no evidence leading to a single 'best' cut-off point. We conclude that the quantitative level of Ki-67 could be used as a prognostic factor in breast-cancer patients.
UR - http://www.scopus.com/inward/record.url?scp=0030758884&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030758884&partnerID=8YFLogxK
U2 - 10.1002/(SICI)1097-0215(19970822)74:4<433::AID-IJC12>3.0.CO;2-A
DO - 10.1002/(SICI)1097-0215(19970822)74:4<433::AID-IJC12>3.0.CO;2-A
M3 - Article
C2 - 9291434
AN - SCOPUS:0030758884
VL - 74
SP - 433
EP - 437
JO - International Journal of Cancer
JF - International Journal of Cancer
SN - 0020-7136
IS - 4
ER -